HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?

Asymchem Laboratories (6821.HK/002821.CH) - A Heartening Rise in Share Price Could Be Drawing Near

China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine

Ping An Healthcare and Technology Company Limited (1833.HK)- To Turn Things Around or to Fail Again?

JD Health (6618.HK) 23H1 - The Beautiful Story Is Over; It's Time to Face Reality

ClouDr Group (9955.HK) 23H1 - Turning Losses into Profits Is Within Reach

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Ping An Healthcare and Technology / Equity Bottom-Up

Ping An Healthcare and Technology (1833 HK)

<ul>
<li>PAGD successfully narrowed net loss. It seems that the Company doesn’t mind “sacrificing” revenue scale, which could be considered "a necessary price" to pay for the transition to 2B model.</li>
<li>PAGD mainly rely on Ping An Group channels to acquire B-end and F-end users, but based on our calculation, PAGD would encounter an obvious growth ceiling at certain revenue scale.</li>
<li>Although PAGD could achieve breakeven by divesting businesses with low strategic synergies and effective cost control, the Company's long-term growth potential and prospects remain uncertain, leading to discounted valuation.  </li>
</ul>


PAGD successfully narrowed net loss. It seems that the Company doesn’t mind “sacrificing” revenue scale, which could be considered "a necessary price" to pay for the transition to 2B model.
PAGD mainly rely on Ping An Group channels to acquire B-end and F-end users, but based on our calculation, PAGD would encounter an obvious growth ceiling at certain revenue scale.
Although PAGD could achieve breakeven by divesting businesses with low strategic synergies and effective cost control, the Company's long-term growth potential and prospects remain uncertain, leading to discounted valuation.  


Ping An Healthcare and Technology (1833.HK) - Valuation Could Fall Again Due to Clear Growth Ceiling